Home » Topics » BioWorld Science

BioWorld Science
RSS

Palobiofarma and Novartis patent adenosine A2A receptor antagonists

Sep. 5, 2018

National Institute of Pharmaceutical R&D divulges BTK ihibitors

Sep. 5, 2018

Development of a new PDE9A inhibitor for the treatment of CNS diseases

Sep. 5, 2018

Ossianix to use BBB delivery technology with agents from Novo Nordisk

Sep. 5, 2018

Positive results reported across multiple endpoints in ZENITH-1 trial of oral BCX-7353

Sep. 5, 2018

Nerlynx approved in Europe as extended adjuvant therapy of HER2-positive early-stage breast cancer

Sep. 5, 2018

Boehringer Ingelheim and Tsinghua University to develop novel therapies against infectious diseases

Sep. 5, 2018

Additional positive data presented from phase IIa study of NasoVAX intranasal influenza vaccine

Sep. 5, 2018

OPKO Health announces initiation of phase II study of Rayaldee in dialysis patients

Sep. 5, 2018

New phase I trial evaluates Inovio's GLS-6150 to prevent hepatitis C

Sep. 5, 2018

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 13, 2026.
FENS 2026: Next-gen biologics take on brain disease
BioWorld
Whether by fine-tuning neurotransmitter signaling or silencing disease-associated genes, emerging biologic therapies are reshaping neuroscience drug development,...
Ionis, AZ shares down on unexpected Wainua flop in cardiomyopathy
BioWorld
News of the unexpected phase III failure of the gene silencing drug Wainua (eplontersen) in the treatment of transthyretin-mediated amyloid cardiomyopathy sent...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
NRF2 activators reported in Vailima Peninsula patent
BioWorld Science
Vailima Peninsula Pty Ltd. has discovered new nuclear factor erythroid 2-related factor 2 (NFE2L2; NRF2) activators potentially useful for the treatment of...